 DecisionBase PDFs --
2008
 Overview:
Ovarian cancer (CaO) is the leading cause of gynecological
cancer death and the fifth-most-frequent cause of cancer death overall in women
in the Western world. The CaO market is a heavily generic market comprising
many combination and single-agent regimens with subtly different clinical
profiles. Nonetheless, opportunity remains for novel agents that can reduce
disease relapse and prolong survival.
Questions Answered in This Report:
 A drug’s performance on at least three efficacy end points,
including overall survival and progression-free survival, is important for drug
approval and physician use. What are the key primary and secondary clinical
trial end points with which new therapies are evaluated? How do oncologists
weight efficacy measures and other drug attributes in their prescribing
decisions for advanced ovarian cancer?
Paclitaxel (Bristol-Myers Squibb’s Taxol, generics) plus
carboplatin (Bristol-Myers Squibb’s Paraplatin, generics) is the 2006
major-market sales leader for advanced CaO. Do thought leaders expect emerging
therapies to offer significant improvements in efficacy, safety and
tolerability, or delivery over paclitaxel plus carboplatin? Which emerging
therapies pose the greatest threat to paclitaxel plus carboplatin?
Based on its clinical profile, paclitaxel plus carboplatin
is the 2006 clinical gold standard in our drug comparator model. What
attributes do thought leaders believe differentiate this drug from competing
current and emerging therapies? Will any drugs in development challenge
paclitaxel plus carboplatin as the future gold standard in 2011 or 2016?
Scope:
Key drug development opportunity tested in our target
product profiles for advanced ovarian cancer: An agent or regimen that offers
increased median overall survival (MOS) compared with paclitaxel/carboplatin
for the treatment of advanced CaO.
Physicians surveyed for this study: 60 U.S. medical oncologists.
Comprehensive List of Therapies Included in Our Research and
Modeling
Current therapies:
- Paclitaxel (Bristol-Myers Squibb’s Taxol, generics) plus
carboplatin (Bristol-Myers Squibb’s Paraplatin, generics)
- Docetaxel (Sanofi-Aventis’s Taxotere) plus carboplatin
(Bristol-Myers Squibb’s Paraplatin, generics)
- Carboplatin (Bristol-Myers Squibb’s Paraplatin, generics)
Emerging therapies:
- Bevacizumab (Roche/Genentech/Chugai’s Avastin) plus
paclitaxel/carboplatin (Bristol-Myers Squibb’s Taxol/Paraplatin)
- Bevacizumab (Roche/Genentech/Chugai’s Avastin)--induction/maintenance
- Phenoxodiol (Marshall Edwards’ Idronoxil)
About DecisionBase
Ovarian Cancer (Advanced): Therapies Must Increase Survival
over Paclitaxel/Carboplatin to Successfully Enter This Generic Market is a
DecisionBase 2008 study from Decision Resources. DecisionBase 2008 combines
market forecasts with clinical and commercial end points to assess market share
projections in 35 indications. These outputs are driven by quantitative and
qualitative primary research. DecisionBase 2008 provides detailed market share,
patient share, and price-per-day projections for emerging drugs in development.
The market share projections are based on prescriber surveys that compare
physicians’ expectations of a potential target product profile with an emerging
product profile of the leading drugs in development.
|
